

BIOLASE, INC  
Form 8-K  
September 02, 2014

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

August 27, 2014

**Biolase, Inc.**

(Exact name of registrant as specified in its charter)

Delaware

000-19627

87-0442441

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

4 Cromwell, Irvine, California

92618

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

949-361-1200

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Top of the Form**

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Board of Directors Committee Assignments

On August 27, 2014, the Board of Directors (the "Board") of Biolase, Inc. (the "Company") appointed Paul N. Clark, a director, to the Audit Committee of the Board. In addition, the Board appointed Dr. Jonathan T. Lord, a director, as a member and chairman of the Compensation Committee of the Board, and appointed directors Drs. Lord and Frederic H. Moll to the Nominating and Corporate Governance Committee of the Board.

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On August 27, 2014, the 2014 Annual Meeting of Stockholders of Biolase, Inc. (the "Company") was held at the Company's headquarters, 4 Cromwell, Irvine, California. The following are the results of the voting on the proposals submitted to stockholders at the Annual Meeting.

1. Stockholders elected all of the Company's four nominees for director, and the one nominee of Oracle Partners, L.P. for director, to serve a one-year term until the 2015 Annual Meeting of Stockholders and until their respective successors are elected and qualified, as set forth below:

Paul N. Clark  
Votes For: 22,026,997  
Votes Withheld: 4,667,131  
Broker Non-votes: 12,199,493

Frederic H. Moll  
Votes For: 22,982,691  
Votes Withheld: 4,632,588  
Broker Non-votes: 12,199,493

Jeffrey M. Nugent  
Votes For: 21,917,032  
Votes Withheld: 4,675,917  
Broker Non-votes: 12,199,493

James R. Talevich  
Votes For: 22,035,641  
Votes Withheld: 4,664,298  
Broker Non-votes: 12,199,493

Jonathan T. Lord  
Votes For: 21,805,002  
Votes Withheld: 4,607,639  
Broker Non-votes: 12,199,493

2. Stockholders ratified the selection of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2014, as set forth below:

Votes For: 35,869,851  
Votes Against: 2,825,666  
Abstentions: 506,641  
Broker Non-votes: 0

3. Stockholders approved the amendment to the Restated Certificate of Incorporation, as set forth below:

## Edgar Filing: BIOLASE, INC - Form 8-K

Votes For: 33,049,827  
Votes Against: 4,311,165  
Abstentions: 1,677,148  
Broker Non-votes: 164,018

4. Stockholders approved the amendment to the 2002 Stock Incentive Plan, as set forth below:

Votes For: 20,938,060  
Votes Against: 4,323,895  
Abstentions: 1,740,710  
Broker Non-votes: 12,199,493

5. Stockholders voted, on an advisory basis, to approve the compensation of the Company's named executive officers, as set forth below:

Votes For: 19,678,064  
Votes Against: 4,988,687  
Abstentions: 2,335,914  
Broker Non-votes: 12,199,493

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Biolase, Inc.

*August 29, 2014*

By: *Frederick D. Furry*

---

*Name: Frederick D. Furry*  
*Title: Chief Financial Officer*